Going From Genome to Pill

See allHide authors and affiliations

Science  24 Jun 2005:
Vol. 308, Issue 5730, pp. 1858-1860
DOI: 10.1126/science.308.5730.1858

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


A new medicine for African Americans with heart failure hints at what the drug industry sees as the enormous payoff from pharmacogenomics.